CIS patients with conversion to clinically definite MS (n = 23) | CIS patients without conversion to clinically definite MS (n = 28) | p | |
---|---|---|---|
Female sex | 17 (73.9%) | 21 (75%) | 0.93 |
Mean age at MS diagnosis (years +/- SEM) | 31.8 +/- 2.2 | 31.0 +/- 2.0 | 0.79 |
Mean age at treatment initiation (years +/- SEM) | 33.4 +/- 2.5 | 32.1 +/- 2.0 | 0.69 |
Mean EDSS at inclusion consultation (+/- SEM) | 1.2 +/- 0.2 | 1.3 +/- 0.2 | 0.77 |
Mean ΔEDSS* (+/- SEM) | +0.2 +/- 0.04 | 0 +/- 0.02 | 0.70 |
Mean MFIS score (+/- SEM) | 36.0 +/- 4.5 | 35.8 +/- 3.3 | 0.98 |
Number of fatigue patients | 13 (56.5%) | 16 (57.1%) | 0.96 |
Mean MADRS score (+/- SEM) | 3.7 +/- 0.8 | 3.2 +/- 0.5 | 0.63 |
Mean MSTCQ score (+/- SEM) | 6.3 +/- 0.8 | 6.3 +/- 0.9 | 0.99 |
Number of NAb + patients | 5 (21.7%) | 7 (25.0%) | 0.78 |
IFNβ type: | |||
- Intramuscular IFNβ-1a | 2 (8.7%) | 3 (10.7%) | 0.43 |
- Subcutaneous IFNβ-1a | 16 (69.6%) | 15 (53.6%) | |
- Subcutaneous IFNβ-1b | 5 (21.7%) | 10 (35.7%) |